Send to

Choose Destination
Cancer Invest. 2014 May;32(4):136-43. doi: 10.3109/07357907.2014.883528. Epub 2014 Feb 28.

Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.

Author information

1Departments of 1Biochemistry.


Serum mass profiling can discern physiological changes associated with specific disease states and their progression. Sera (86 total) from control individuals and patients with stage I nonsmall cell lung cancer or benign small pulmonary nodules were discriminated retrospectively by serum changes discerned by mass profiling. Control individuals were distinguished from patients with Stage I lung cancer or benign nodules with test sensitivities of 89% and 83%. Lung cancer patients versus those with benign nodules were distinguished with 80% sensitivity. This study exhibits progress toward a minimally-invasive aid in early detection of lung cancer and monitoring small pulmonary nodules for malignancy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center